|
1
|
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
|
N Engl J Med
|
2006
|
17.08
|
|
2
|
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
|
N Engl J Med
|
2011
|
13.74
|
|
3
|
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
|
Lancet Oncol
|
2012
|
5.43
|
|
4
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
|
N Engl J Med
|
2015
|
4.97
|
|
5
|
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
|
J Clin Oncol
|
2006
|
4.87
|
|
6
|
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
|
Breast Cancer Res Treat
|
2008
|
4.84
|
|
7
|
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
|
J Clin Oncol
|
2007
|
4.23
|
|
8
|
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2009
|
4.12
|
|
9
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
|
Lancet Oncol
|
2013
|
3.87
|
|
10
|
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.
|
Nat Med
|
2009
|
3.86
|
|
11
|
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
|
J Clin Oncol
|
2013
|
3.81
|
|
12
|
Retracted
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
|
Lancet Oncol
|
2007
|
3.67
|
|
13
|
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
|
J Clin Oncol
|
2009
|
2.88
|
|
14
|
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
|
J Clin Oncol
|
2006
|
2.86
|
|
15
|
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
|
J Clin Oncol
|
2009
|
2.65
|
|
16
|
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
|
J Clin Oncol
|
2004
|
2.39
|
|
17
|
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
|
J Clin Oncol
|
2010
|
2.03
|
|
18
|
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
|
Lancet Oncol
|
2012
|
1.91
|
|
19
|
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
|
Adv Ther
|
2013
|
1.90
|
|
20
|
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
|
J Clin Oncol
|
2010
|
1.74
|
|
21
|
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
|
Clin Cancer Res
|
2013
|
1.68
|
|
22
|
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods.
|
J Neurooncol
|
2009
|
1.64
|
|
23
|
FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
|
Eur J Nucl Med Mol Imaging
|
2011
|
1.60
|
|
24
|
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
|
Oncologist
|
2010
|
1.52
|
|
25
|
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
|
J Clin Oncol
|
2010
|
1.52
|
|
26
|
Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases.
|
Asia Pac J Clin Oncol
|
2010
|
1.47
|
|
27
|
Decoding and unlocking the BCL-2 dependency of cancer cells.
|
Nat Rev Cancer
|
2013
|
1.36
|
|
28
|
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
|
J Clin Oncol
|
2007
|
1.27
|
|
29
|
A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.
|
Mol Cell Proteomics
|
2011
|
1.27
|
|
30
|
bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer.
|
Breast Cancer Res Treat
|
2011
|
1.22
|
|
31
|
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
|
J Neurooncol
|
2011
|
1.17
|
|
32
|
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
|
Breast Cancer Res
|
2012
|
1.16
|
|
33
|
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.
|
Target Oncol
|
2012
|
1.13
|
|
34
|
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
|
Clin Breast Cancer
|
2013
|
1.11
|
|
35
|
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
|
J Natl Cancer Inst
|
2013
|
1.10
|
|
36
|
Vinflunine: a new microtubule inhibitor agent.
|
Clin Cancer Res
|
2008
|
1.09
|
|
37
|
Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
|
Proteomics
|
2006
|
1.08
|
|
38
|
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
|
Clin Cancer Res
|
2011
|
1.08
|
|
39
|
CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer.
|
Cancer Res
|
2013
|
1.07
|
|
40
|
bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses.
|
Database (Oxford)
|
2013
|
1.05
|
|
41
|
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
|
Breast Cancer Res Treat
|
2013
|
0.99
|
|
42
|
Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study.
|
Int J Cancer
|
2011
|
0.97
|
|
43
|
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
|
Breast Cancer Res Treat
|
2013
|
0.97
|
|
44
|
Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
|
Int J Oncol
|
2012
|
0.95
|
|
45
|
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.94
|
|
46
|
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.
|
Breast Cancer Res
|
2011
|
0.91
|
|
47
|
Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis.
|
Crit Rev Oncol Hematol
|
2008
|
0.91
|
|
48
|
mTOR inhibitors in advanced breast cancer: ready for prime time?
|
Cancer Treat Rev
|
2013
|
0.91
|
|
49
|
Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.
|
PLoS One
|
2011
|
0.90
|
|
50
|
Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
|
J Immunother
|
2005
|
0.88
|
|
51
|
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
|
Breast Cancer Res Treat
|
2008
|
0.87
|
|
52
|
Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
|
Breast
|
2011
|
0.85
|
|
53
|
Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.
|
Am J Clin Oncol
|
2009
|
0.85
|
|
54
|
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.
|
Oncologist
|
2013
|
0.84
|
|
55
|
γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
|
Breast Cancer Res
|
2012
|
0.83
|
|
56
|
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
|
Oncologist
|
2012
|
0.82
|
|
57
|
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.82
|
|
58
|
Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study.
|
Int J Oncol
|
2012
|
0.82
|
|
59
|
Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study.
|
Hum Pathol
|
2006
|
0.82
|
|
60
|
Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.
|
Crit Rev Oncol Hematol
|
2011
|
0.82
|
|
61
|
Folate supplementation limits the tumourigenesis in rodent models of gliomagenesis.
|
Eur J Cancer
|
2012
|
0.81
|
|
62
|
Vinflunine: a novel antitubulin agent in solid malignancies.
|
Expert Opin Investig Drugs
|
2005
|
0.80
|
|
63
|
Brain metastases from HER2-positive breast cancer - authors' reply.
|
Lancet Oncol
|
2013
|
0.80
|
|
64
|
Eribulin mesylate for the treatment of late-stage breast cancer.
|
Expert Opin Pharmacother
|
2011
|
0.80
|
|
65
|
Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence.
|
Clin Biochem
|
2012
|
0.79
|
|
66
|
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
|
Clin Cancer Res
|
2009
|
0.79
|
|
67
|
Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer.
|
Cytokine
|
2009
|
0.78
|
|
68
|
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
|
Lancet Oncol
|
2011
|
0.78
|
|
69
|
[Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?].
|
Bull Cancer
|
2005
|
0.78
|
|
70
|
Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
|
BMC Cancer
|
2013
|
0.76
|
|
71
|
Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer.
|
Curr Clin Pharmacol
|
2011
|
0.75
|
|
72
|
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
|
Breast Cancer Res Treat
|
2014
|
0.75
|
|
73
|
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
|
Anticancer Drugs
|
2016
|
0.75
|
|
74
|
Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation.
|
Transplantation
|
2016
|
0.75
|
|
75
|
[Targeting ErbB receptors in breast cancer].
|
Bull Cancer
|
2007
|
0.75
|
|
76
|
What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?
|
Expert Rev Anticancer Ther
|
2012
|
0.75
|